stockrow
Saturday 7 November 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024.
- Revenue
- +992.4%
- EPS
- −26.5%
- Free cash flow
- +0.12%
- Total debt
- +77.6%
Quarter to June 2026, against a year earlier
85.46
5.18
+6.45%
Follow INBX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 2 | 0 | 1 | 3 | (0.4%) | 36 | 36 | 121 | +352.9% | |
| Gross margin, % | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | (115) | (240) | 1,688 | (140) | (138) | +6.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | (8,769.73) | (13,318.00) | 843,787.00 | (10,773.31) | 0.00 | (2,003.6) pt | ||||||
| Net income | — | — | — | — | — | — | (115) | (241) | 1,688 | (140) | (138) | +6.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.15 | 0.01 | 0.08 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (20.48) | 114.01 | (9.04) | (8.88) | (33.6%) | ||||||
| Cash flow | — | — | — | — | — | — | 0.00 | (16.41) | (13.13) | (8.38) | (8.42) | n/m | ||||||
| Capex | — | — | — | — | — | — | 0.00 | (0.39) | (0.18) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | 0.00 | (16.80) | (13.31) | (8.38) | (8.42) | n/m | ||||||
| Book value | — | — | — | — | — | — | 0.00 | 3.69 | 9.02 | 0.52 | (3.38) | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 12 | 15 | 15 | 16 | +14.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 115.71 | 388.28 | 424.97 | 126.0 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 1.71 | 153.07 | 0.00 | 38.7 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 143.31 | 380.77 | 438.60 | 131.0 | ||||||
| EV/FCF | — | — | — | — | — | — | (0.70) | (0.70) | (1.43) | (9.24) | (10.48) | (3.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (91) | (193) | (194) | (130) | (132) | +12.6% | |||||
| Capex | — | — | — | — | — | — | (1) | (5) | (3) | 0 | 0 | (65.6%) | ||||||
| Free cash flow | — | — | — | — | — | — | (91) | (198) | (197) | (130) | (132) | +12.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (15) | 239 | 120 | 99 | 114 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | (71) | (153) | (24) | 43 | (42.3%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (7) | 44 | 134 | 8 | (53) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (148.74) | 690.69 | (85.60) | (75.44) | (85.6) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (1,333.38) | 1,905.92 | (197.85) | (1,773.60) | (197.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 163 | 161 | 110 | — | (17.9%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2025 · fundamentals updated 26 Oct 2026
Inhibrx Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.2B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.2B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| RAPP Rapport Therapeutics, Inc. | $1.1B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SGP SpyGlass Pharma, Inc. | $1.1B | — (loss-making) | — | — | n/m | −100.49% (below 0%: shrinking) | — | 0.00% | Compare |
| VSTM Verastem, Inc. | $1.1B | — (loss-making) | — (loss-making) | +113.59% (above 0%: growing) | n/m | +24.50% (above 0%: growing) | 0.00% | (313.28%) | Compare |
| Median of peers | $1.2B | — | — | — | — | −64.75% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
18.26%
Entities affiliated with Viking Global Opportunities Illiquid Investments Sub-Master LP
10.05%
Entities affiliated with Perceptive Life Sciences Master Fund, Ltd.
9.99%
Inhibrx, Inc.
8.00%
Entities affiliated with Morgan Stanley
7.98%
Jon Faiz Kayyem, Ph.D.
7.53%
Mark P. Lappe
7.29%
Entities affiliated with BlackRock, Inc.
5.31%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement